Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Average (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Equity Average for 6 consecutive years, with $133.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 43.17% to $133.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.6 million, a 43.17% decrease, with the full-year FY2025 number at $182.0 million, down 7.08% from a year prior.
  • Equity Average was $133.6 million for Q4 2025 at TScan Therapeutics, down from $160.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $242.2 million in Q3 2024 to a low of -$55.0 million in Q2 2021.
  • A 5-year average of $136.3 million and a median of $146.0 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 533.15% in 2021, then crashed 43.17% in 2025.
  • TScan Therapeutics' Equity Average stood at $167.4 million in 2021, then crashed by 35.47% to $108.0 million in 2022, then surged by 48.01% to $159.9 million in 2023, then skyrocketed by 46.97% to $235.0 million in 2024, then plummeted by 43.17% to $133.6 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Equity Average are $133.6 million (Q4 2025), $160.4 million (Q3 2025), and $193.5 million (Q2 2025).